Celiac Panel: Evidence-Based Ways to Improve Your Numbers

What a Celiac Panel Actually Measures

A celiac panel is a blood test that detects antibodies your immune system generates when it reacts to gluten, a protein found in wheat, barley, and rye. The core components include tissue transglutaminase IgA (tTG-IgA), deamidated gliadin peptide antibodies (DGP-IgA and DGP-IgG), endomysial antibody (EMA-IgA), and total serum IgA.

The tTG-IgA test is the recommended first-line serologic screen. The American College of Gastroenterology (ACG) 2023 clinical guidelines state that tTG-IgA "is the single preferred serologic test for the detection of celiac disease in individuals aged 2 years and older" 1. Its sensitivity ranges from 95% to 98%, with specificity between 95% and 97% 2. Total serum IgA is measured alongside tTG-IgA because approximately 2-3% of celiac patients have selective IgA deficiency, which can produce false-negative tTG-IgA results 3. In those patients, DGP-IgG or tTG-IgG becomes the preferred marker.

EMA-IgA is highly specific (approaching 99%) but less sensitive and more expensive, so it is typically used as a confirmatory test rather than a standalone screen 2.

A "positive" celiac panel does not by itself confirm the diagnosis. Small bowel biopsy showing villous atrophy (Marsh grade 3) remains the gold standard for adults, though the ACG guidelines note that biopsy may be avoided in children with tTG-IgA levels ≥10 times the upper limit of normal plus a positive EMA on a separate blood draw 1.

Normal Celiac Panel Ranges

Normal ranges vary slightly by laboratory and assay manufacturer, but the general thresholds are consistent. A tTG-IgA below 4 U/mL is negative in most commercial assays. Values between 4 and 10 U/mL are considered weak positives and warrant further workup. Values above 10 U/mL are positive.

For DGP-IgA and DGP-IgG, typical negative cutoffs fall below 20 U. EMA results are reported qualitatively as positive or negative. Total serum IgA reference ranges for adults are 70 to 400 mg/dL; values below 7 mg/dL suggest selective IgA deficiency 3.

A 2019 meta-analysis published in Gastroenterology evaluated 96 studies and confirmed that tTG-IgA at a threshold of 10x the upper limit of normal had a pooled positive predictive value exceeding 95% for villous atrophy in adults 4. That level of confidence is what allowed guidelines to begin discussing biopsy-sparing approaches for select pediatric populations. The numbers matter. A tTG-IgA of 6 U/mL in a low-risk patient carries a very different clinical weight than a tTG-IgA of 150 U/mL in someone with chronic diarrhea and iron deficiency.

Strict Gluten-Free Diet: The Primary Intervention

A strict gluten-free diet is the only proven treatment for celiac disease and the only reliable way to normalize celiac panel antibodies. This is not a "low-gluten" or "mostly gluten-free" approach. Even 50 mg of gluten per day (roughly 1/100th of a standard slice of bread) can sustain intestinal inflammation and keep antibody levels elevated 5.

The results of strict adherence are well documented. A prospective study of 241 adults with biopsy-confirmed celiac disease found that 83% achieved tTG-IgA normalization within 12 months of starting a strict GFD 6. Antibody levels begin dropping within the first 3 months and typically reach a plateau between 6 and 12 months. Patients with very high baseline tTG-IgA levels (≥100 U/mL) may take up to 18 to 24 months to fully normalize 7.

Dr. Benjamin Lebwohl, Director of Clinical Research at the Celiac Disease Center at Columbia University, has noted: "Persistent antibody elevation after 12 months on a GFD most often reflects ongoing gluten exposure, whether intentional or inadvertent" 8.

Hidden gluten sources are the most common reason for non-normalizing antibodies. These include soy sauce, malt flavoring, certain medications and supplements, communion wafers, shared cooking surfaces, and processed oats not certified gluten-free. Working with a registered dietitian who specializes in celiac disease significantly improves adherence. A randomized trial of 212 newly diagnosed celiac patients showed that those who received structured dietitian counseling had a 23% higher rate of antibody normalization at 12 months compared to those who received standard physician advice alone 9.

Nutritional Repletion: Fixing What Gluten Damaged

Celiac disease damages the proximal small intestine, the primary site for absorbing iron, folate, calcium, and fat-soluble vitamins. Even after starting a GFD, nutritional deficiencies can persist for months. Correcting them does not directly lower celiac antibodies, but it is essential for full clinical recovery and for supporting the intestinal healing that drives antibody normalization.

Iron deficiency is present in 30-50% of newly diagnosed celiac patients 10. Ferritin should be checked at diagnosis and every 6 months until stable. Oral iron supplementation (ferrous sulfate 325 mg daily or every other day) is first-line, though some patients need IV iron if absorption remains poor.

Vitamin D deficiency affects roughly 60-75% of celiac patients at diagnosis 11. The Endocrine Society recommends repletion with 50,000 IU of ergocalciferol weekly for 8 weeks in adults with 25(OH)D levels below 20 ng/mL, followed by maintenance dosing of 1,500 to 2,000 IU daily 12. Calcium intake should target 1,000 to 1,200 mg daily from food and supplements combined, given the overlap between celiac disease and reduced bone mineral density.

Folate and B12 deserve attention as well. A study of 423 adults with newly diagnosed celiac disease found folate deficiency in 20% and B12 deficiency in 12% 10. Both should be checked at baseline. Zinc deficiency, while less frequently measured, is common and contributes to impaired mucosal healing.

Monitoring: When to Retest and What to Expect

Serial antibody testing is the primary tool for tracking response to a GFD. The ACG recommends rechecking tTG-IgA at 6 months after diagnosis and GFD initiation, then annually 1.

Here is a realistic timeline. At 3 months, tTG-IgA should show a downward trend, though it may still be above normal. At 6 months, most compliant patients will have values near or within the normal range. At 12 months, 80-85% of strictly adherent patients will have fully normal tTG-IgA. At 24 months, antibody normalization rates reach 90-95% in those with confirmed adherence 6.

If tTG-IgA remains elevated at 12 months, the first step is a detailed dietary review with a celiac-specialized dietitian. Gluten immunogenic peptide (GIP) testing, available in urine and stool, can detect recent gluten ingestion with higher sensitivity than patient self-reporting 13. A study of 188 celiac patients on a self-reported strict GFD found that 30% had detectable urinary GIP, indicating unrecognized gluten exposure 13.

Persistent antibody elevation beyond 24 months despite confirmed adherence (verified by negative GIP testing and dietitian review) raises the possibility of refractory celiac disease, which affects 1-2% of celiac patients and requires gastroenterology subspecialty evaluation 14.

The Hypothyroid and Autoimmune Overlap

Celiac disease frequently coexists with other autoimmune conditions. The most clinically relevant overlap is with autoimmune thyroid disease. Approximately 2-5% of celiac patients have coexisting Hashimoto's thyroiditis, and conversely, celiac prevalence in autoimmune thyroid disease runs 2-4 times higher than in the general population 15.

This matters for antibody interpretation. A patient with persistently mildly elevated tTG-IgA and concurrent autoimmune thyroid disease should have thyroid antibodies (TPO, thyroglobulin) and TSH checked. Poorly controlled hypothyroidism can impair GI motility and mucosal repair, indirectly slowing antibody normalization. The American Thyroid Association recommends screening for celiac disease in patients with autoimmune thyroid disease who present with unexplained iron deficiency, GI symptoms, or weight loss 16.

Patients with type 1 diabetes have a celiac disease prevalence of 5-8%, and the American Diabetes Association recommends screening with tTG-IgA soon after diabetes diagnosis 17. In these patients, improving celiac antibodies through a strict GFD may also improve glycemic variability.

What Does Not Work

Several approaches lack evidence for improving celiac panel numbers and should be avoided as substitutes for a GFD.

Digestive enzyme supplements marketed as "gluten-digesting" (such as DPP-IV-containing products) do not break down enough gluten to prevent immunologic responses. A randomized, double-blind, placebo-controlled trial found that AN-PEP enzyme taken with a gluten challenge did not reduce tTG-IgA elevation compared to placebo 18. These products may provide a false sense of security.

Probiotics have shown mixed results. While certain strains (Bifidobacterium infantis) may reduce GI symptoms in celiac patients on a GFD, no probiotic has been shown to lower celiac antibody levels in controlled trials 19. They are not a substitute for dietary compliance.

"Gluten desensitization" or "gluten tolerance" protocols have no supporting evidence in peer-reviewed literature and are not recommended by any major gastroenterology society. The immune response in celiac disease is fundamentally different from IgE-mediated food allergy, making tolerance induction inapplicable.

Emerging Therapies in Development

Several investigational therapies aim to supplement (not replace) the GFD. None are FDA-approved for celiac disease as of May 2026.

Latiglutenase is an enzyme therapy designed to degrade immunotoxic gluten peptides before they reach the intestinal mucosa. The phase 2b ALV003-1221 trial (N=494) showed reduced mucosal injury in seropositive celiac patients on a GFD, though the primary symptom endpoint was not met 20. Phase 3 studies are ongoing.

TAK-101 (now CALY-002) uses nanoparticles loaded with gliadin to induce immune tolerance. A phase 2 trial showed attenuation of gluten-induced mucosal damage compared to placebo after a 14-day gluten challenge 21. This approach is years from potential approval.

ZED1227, a transglutaminase 2 inhibitor, targets the enzyme that generates the immunogenic gluten epitopes. A phase 2a trial (N=160) demonstrated significant protection against gluten-induced mucosal damage over 6 weeks 22. The concept of blocking the autoantigen-generating enzyme is novel and the data are promising.

None of these therapies will eliminate the need for a GFD. They are being developed as adjuncts for patients who experience persistent symptoms or antibody elevation despite best dietary efforts.

Building a Follow-Up Plan That Works

A practical monitoring schedule makes the difference between antibody normalization and years of frustration. At diagnosis, draw a complete celiac panel (tTG-IgA, DGP-IgA, DGP-IgG, EMA-IgA, total IgA), along with a CBC, iron studies, folate, B12, 25(OH)D, calcium, magnesium, zinc, liver enzymes, and TSH. Schedule a dietitian referral within the first 2 weeks. At 3 months, recheck tTG-IgA to confirm a downward trend and address any persistent symptoms. At 6 months, recheck tTG-IgA and all deficient nutrients. If tTG-IgA has not dropped by at least 50% from baseline, pursue a formal dietary review and consider GIP testing. At 12 months, a normalized tTG-IgA confirms healing is on track. Annual tTG-IgA testing continues lifelong. Bone density screening (DEXA) is recommended at diagnosis or within the first year for adults, per ACG guidelines 1.

The 2023 ACG guidelines note that "normalization of celiac serologies while on a GFD is a surrogate marker for mucosal healing and is associated with reduced long-term complications including lymphoma and osteoporotic fracture" 1. That single sentence captures the stakes. These numbers are not abstract. They track real tissue damage.

Patients whose tTG-IgA normalizes within 12 months and who remain on a strict GFD have a long-term complication risk that approaches the general population baseline 23.